Arhalofenate

Arhalofenate
Identifiers
	IUPAC name 2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate;
CAS Number	24136-23-0;
PubChem CID	12082259;
DrugBank	DB11811;
ChemSpider	28528987;
UNII	1P01UJR9X1;
KEGG	D09579;
ChEMBL	ChEMBL2103824;
CompTox Dashboard (EPA)	DTXSID301347353 ;
ECHA InfoCard	100.216.298
Chemical and physical data
Formula	C19H17ClF3NO4
Molar mass	415.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)NCCOC(=O)[C@@H](C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F;
	InChI InChI=InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1; Key:BJBCSGQLZQGGIQ-QGZVFWFLSA-N;

Arhalofenate is a dual-acting small molecule being developed by CymaBay Therapeutics for the treatment of gout, offering both urate-lowering and anti-inflammatory effects. As a uricosuric agent, arhalofenate lowers serum urate by inhibiting its reabsorption in the proximal tubules of the kidney through blockade of transporters such as URAT1, OAT4, and OAT10.^[1] Arhalofenate also suppresses gout flares by inhibiting the urate crystal–stimulated release of interleukin-1β (IL-1β), the key cytokine responsible for triggering gout attacks.^[2]

References

^ Wang G, Zuo T, Li R (November 2020). "The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity". Drug Development Research. 81 (7): 859–866. doi:10.1002/ddr.21699. PMID 32506648.
^ Yip K, Braverman G, Yue L, Fields T (March 2024). "Pipeline Therapies for Gout". Current Rheumatology Reports. 26 (3): 69–80. doi:10.1007/s11926-023-01128-3. PMID 38133712.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[:1-1] Wang G, Zuo T, Li R (November 2020). "The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity". Drug Development Research. 81 (7): 859–866. doi:10.1002/ddr.21699. PMID 32506648.

[pmid38133712-2] Yip K, Braverman G, Yue L, Fields T (March 2024). "Pipeline Therapies for Gout". Current Rheumatology Reports. 26 (3): 69–80. doi:10.1007/s11926-023-01128-3. PMID 38133712.

[1]

[2]